Burosumab
Crysvita (burosumab) is an antibody pharmaceutical. Burosumab was first approved as Crysvita on 2018-02-19. It has been approved in Europe to treat familial hypophosphatemia and familial hypophosphatemic rickets. The pharmaceutical is active against fibroblast growth factor 23.
| Trade Name | Crysvita |
|---|---|
| Common Name | Burosumab |
| Indication | familial hypophosphatemia, familial hypophosphatemic rickets |
| Drug Class | Monoclonal antibodies: fully human, bone target |
